Global Influenza Treatment Market is expected to grow at a CAGR of 2.4% during the forecast period 2020-2027
A new research report published by Fior Markets with the title Global Influenza Treatment Market by Product (Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Laninamivir Octanoate), Distribution Channel (Hospitals, Clinics, and Pharmacies), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027.
The global influenza treatment market is expected to grow from USD 910 million in 2019 to USD 1,101 million by 2027, at a CAGR of 2.4% during the forecast period 2020-2027. North America is expected to dominate the market with the widespread prevalence of the disease in the region. The increasing investments in the research and development sector for combating the severe illness and growing awareness about the severity of the disease in the population will drive the growth of the market in the region. Along with this, the companies are launching new products that will help the market to grow. The Asia-Pacific region is expected to show the highest growth rate due to a rise in the levels of disposable incomes of the people and rising healthcare expenditure. The increasing government initiatives to prevent and cure the disease will also fuel the market growth.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418393/request-sample
The leading players of the market include Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Sandoz International GmbH (Novartis AG), Teva Pharmaceutical Industries Ltd., Mylan Inc., and Sun Pharmaceutical Industries Ltd. The companies are focusing on the development of improved technological medications, competitive pricing, and mergers and acquisitions.
On the basis of product, the market is divided into zanamivir, oseltamivir, peramivir, amantadine, rimantadine, inosine, and laninamivir octanoate. The oseltamivir holds the largest market share due to its increasing use in the treatment of flu caused by prophylaxis and H1N1 virus. On the basis of distribution channels, the market is divided into hospitals, clinics, and pharmacies. The pharmacies hold a dominant share in the market as the patients after being diagnosed at the hospitals or clinics undertake the prescribed medication from the retail or online pharmacies. The pharmacies provide efficient services with the availability of major products required to treat the disease. The hospitals also hold a significant share with the increase in the number of patients with illnesses related to influenza, like CVDs and HIV.
With increasing investments in the research and development of improved drugs and treatment, the market will grow substantially. With the increase in the number of people getting affected by the flu every year, the government is making several policies for the prevention of disease and its effective treatment acting as a significant driver for market growth. The awareness regarding the seriousness of the condition and its health impacts has been increasing, leading to further development of advanced technology for treatment.
About the report:
The global influenza treatment market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional, and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire